“On Trk” - the TrkB signal transduction pathway is an increasingly important target in cancer biology

ανά Thiele, Carol J., Li, Zhijie, McKee, Amy E.
Έκδοση 2009

The FDA Oncology Center of Excellence and precision medicine

ανά Goldberg, Kirsten B, Blumenthal, Gideon M, McKee, Amy E, Pazdur, Richard
Τόπος έκδοσης Exp Biol Med (Maywood) (2017)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies

ανά Blumenthal, Gideon M., Kluetz, Paul G., Schneider, Julie, Goldberg, Kirsten B., McKee, Amy E., Pazdur, Richard
Τόπος έκδοσης Oncologist (2017)

Successes and Challenges of PARP Inhibitors in Cancer Therapy

ανά Ricks, Tiffany K., Chiu, Haw-Jyh, Ison, Gwynn, Kim, Geoffrey, McKee, Amy E., Kluetz, Paul, Pazdur, Richard
Τόπος έκδοσης Front Oncol (2015)

An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies

ανά Beaver, Julia A., Tzou, Abraham, Blumenthal, Gideon M., McKee, Amy E., Kim, Geoffrey, Pazdur, Richard, Philip, Reena
Τόπος έκδοσης Clin Cancer Res (2016)

FDA Approval Summary: Lenalidomide as Maintenance Therapy After Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

ανά Pulte, Elizabeth Dianne, Dmytrijuk, Andrew, Nie, Lei, Goldberg, Kirsten B., McKee, Amy E., Farrell, Ann T., Pazdur, Richard
Τόπος έκδοσης Oncologist (2018)

U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Re...

ανά Pulte, E. Dianne, Wroblewski, Tanya, Bloomquist, Erik, Tang, Shenghui, Farrell, Ann, Deisseroth, Albert, McKee, Amy E., Pazdur, Richard
Τόπος έκδοσης Oncologist (2019)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia

ανά Pulte, E. Dianne, Vallejo, Jonathon, Przepiorka, Donna, Nie, Lei, Farrell, Ann T., Goldberg, Kirsten B., McKee, Amy E., Pazdur, Richard
Τόπος έκδοσης Oncologist (2018)

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1

ανά Fashoyin‐Aje, Lola, Donoghue, Martha, Chen, Huanyu, He, Kun, Veeraraghavan, Janaki, Goldberg, Kirsten B., Keegan, Patricia, McKee, Amy E., Pazdur, Richard
Τόπος έκδοσης Oncologist (2018)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

ανά Kasamon, Yvette L., Ko, Chia‐Wen, Subramaniam, Sriram, Ma, Lian, Yang, Yuching, Nie, Lei, Shord, Stacy, Przepiorka, Donna, Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Τόπος έκδοσης Oncologist (2018)

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation

ανά Oneal, Patricia A., Kwitkowski, Virginia, Luo, Lola, Shen, Yuan Li, Subramaniam, Sriram, Shord, Stacy, Goldberg, Kirsten B., McKee, Amy E., Kaminskas, Edvardas, Farrell, Ann, Pazdur, Richard
Τόπος έκδοσης Oncologist (2018)

FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chem...

ανά Larkins, Erin, Blumenthal, Gideon M., Yuan, Weishi, He, Kun, Sridhara, Rajeshwari, Subramaniam, Sriram, Zhao, Hong, Liu, Chao, Yu, Jingyu, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Τόπος έκδοσης Oncologist (2017)

FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy

ανά Bhatnagar, Vishal, Gormley, Nicole J., Luo, Lola, Shen, Yuan Li, Sridhara, Rajeshwari, Subramaniam, Sriram, Shen, Guoxiang, Ma, Lian, Shord, Stacy, Goldberg, Kirsten B., Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Τόπος έκδοσης Oncologist (2017)

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond

ανά Pai‐Scherf, Lee, Blumenthal, Gideon M., Li, Hongshan, Subramaniam, Sriram, Mishra‐Kalyani, Pallavi S., He, Kun, Zhao, Hong, Yu, Jingyu, Paciga, Mark, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Τόπος έκδοσης Oncologist (2017)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

ανά Pelosof, Lorraine, Lemery, Steven, Casak, Sandra, Jiang, Xiaoping, Rodriguez, Lisa, Pierre, Vadryn, Bi, Youwei, Liu, Jiang, Zirkelbach, Jeanne Fourie, Patel, Anuja, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Τόπος έκδοσης Oncologist (2018)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

ανά Odogwu, Lauretta, Mathieu, Luckson, Blumenthal, Gideon, Larkins, Erin, Goldberg, Kirsten B., Griffin, Norma, Bijwaard, Karen, Lee, Eunice Y., Philip, Reena, Jiang, Xiaoping, Rodriguez, Lisa, McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Τόπος έκδοσης Oncologist (2018)

FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin‐Containing Chemotherapy

ανά Suzman, Daniel L., Agrawal, Sundeep, Ning, Yang‐min, Maher, V. Ellen, Fernandes, Laura L., Karuri, Stella, Tang, Shenghui, Sridhara, Rajeshwari, Schroeder, Jason, Goldberg, Kirsten B., Ibrahim, Amna, McKee, Amy E., Pazdur, Richard, Beaver, Julia A.
Τόπος έκδοσης Oncologist (2018)

NCCN Work Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies

ανά Venook, Alan P., Arcila, Maria E., Benson, Al B., Berry, Donald A., Camidge, David Ross, Carlson, Robert W., Choueiri, Toni K., Guild, Valerie, Kalemkerian, Gregory P., Kurzrock, Razelle, Lovly, Christine M., McKee, Amy E., Morgan, Robert J., Olszanski, Anthony J., Redman, Mary W., Stearns, Vered, McClure, Joan, Birkeland, Marian L.
Τόπος έκδοσης J Natl Compr Canc Netw (2014)